Tolvaptan: Phase III data
In the double-blind, placebo-controlled, international Phase III EVEREST trial in 4,133 patients, long-term therapy with 30 mg of once-daily
Gathering data...
In the double-blind, placebo-controlled, international Phase III EVEREST trial in 4,133 patients, long-term therapy with 30 mg of once-daily